ACE ImmunoID. ACE ImmunoID. Precision immunogenomics. Precision Genomics for Immuno-Oncology
|
|
- Leona Morris
- 5 years ago
- Views:
Transcription
1 ACE ImmunoID ACE ImmunoID Precision immunogenomics Precision Genomics for Immuno-Oncology
2 Personalis, Inc. A universal biomarker platform for immuno-oncology Patient response to cancer immunotherapies is currently reported as falling anywhere between 8% and 20% 1,2. Understanding the mechanisms by which tumors can evade the immune response and elucidating the complex dynamics of the tumor and its microenvironment are key to improving this success rate. ACE ImmunoID is designed to meet this need. The ACE ImmunoID Platform integrates augmented exome and transcriptome sequencing from a paired tumor and normal sample to generate comprehensive genomic and transcriptomic data that can be used for neoantigen selection and tumor immunogenomic profiling. The result? A universal platform to support the development of more effective cancer immunotherapies by identifying biomarkers that can be used to stratify patient populations, determining rational therapy combinations, and developing truly personalized therapeutics. Precision immunogenomics You need to answer complex biological questions. This requires precise and accurate genomic data. Our patented Accuracy and Content Enhanced (ACE ) Technology 3 improves processes including nucleic extraction, library creation, sequencing, and analytics, and is the foundational platform powering ACE ImmunoID. By optimizing each step of genomics laboratory and bioinformatics analysis processes, we re ensuring that you get the most complete data from your precious samples. Make the most of your precious samples Patient samples can vary in quality and unlocking genomic insights from these critical samples can be challenging. Our ACE Technology improves sample preparation and nucleic acid extraction processes, even when working with samples which may be archival and/or partially degraded.
3 ACE ImmunoID ACE ImmunoID requires paired tumor and normal (T/N) samples for analysis. Our proprietary sample-sparing approach enables us to extract DNA and RNA from the same tumor sample. DNA is additionally extracted from the normal sample, providing a germline baseline which is used to more precisely identify tumor-specific somatic mutations. Additionally, Personalis has developed protocols to overcome the challenges of working with diverse sample types including formalin-fixed and paraffin-embedded (FFPE), fine-needle aspirates (FNAs), fresh frozen, and peripheral blood mononuclear cells (PBMCs). With respect to cancer studies, FFPE specimens are often the only tumor sample type available. Unfortunately, the fixation process can contribute to the degradation of both DNA and RNA. To accommodate for any variation in sample quality, each sample undergoes robust QC. At Personalis, metrics such as percent of mapped reads, Qmap score, and Qbase score are evaluated when assessing sequencing results. Figure 1 below illustrates QC metrics for a recent project performed at Personalis using our ACE Cancer Exome assay across 130 randomlyselected FFPE samples that varied in terms of quality (amount, age). The metrics below convey that the data quality of the DNA extracted from these challenging samples was high in more than 92% of these samples. Figure 1: Personalis sample quality metrics in a randomly selected cohort of 130 FFPE specimens Footnotes 1. Gay, N. and V. Prasad. Few people actually benefit from breakthrough cancer immunotherapy. Stat. March 8, com/2017/03/08/immunotherapy-cancer-breakthrough/. 2. Lee Ventola, C. Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations. Pharmacy and Therapeutics Jul; 42(7): ACE Technology has patent approval world-wide including the United States, Europe, and China. Precision Genomics for Immuno-Oncology
4 Personalis, Inc. We ve taken the same precautions to ensure that RNA data quality is equally high. Whether fresh frozen or fixed specimens are available for your analysis, the ACE approach produces high quality transcriptome sequencing results. Using paired FFPE and matched adjacent fresh frozen tissues, we found high correlation of normalized gene expression (TPM) (Figure 2) across various tumor types. This data demonstrates that the Personalis ACE Cancer Transcriptome is an accurate, reliable method for characterizing gene expression in even the most challenging materials such as FFPE. Figure 2: Correlation plots of log 2 transcripts per million (TPM) between matched FF (x-axis) and FFPE (y-axis) pairs in A-D) colon, E) lung, and F) rectum tumor samples. ACE sequencing improvements The ACE ImmunoID platform combines our ACE Cancer Exome and ACE Cancer Transcriptome assays for more complete genomic and transcriptomic data compared to standard exome assays. Most commercially-available exome assays have significant sequencing coverage gaps due to systematic sequencing biases. Personalis has custom-developed targeted capture with additional optimized chemistry, as part of our ACE Technology, to augment and fix gaps in the exome across more than 8,000 of the ~20,000 genes. This augmented sequencing decreases the risk of missed variants and more precisely captures putative neoantigens.
5 ACE ImmunoID ACE Cancer Exome When used as a component of the ACE ImmunoID Platform, the ACE Cancer Exome is available as a paired tumor and normal configuration and is sequenced at a guaranteed average depth of 200x for the tumor and 70x for the normal. Our assay outperforms conventional exome assays by augmenting coverage again made possible using our ACE technology across more than 8,000 genes which are poorly covered by conventional approaches. This superior coverage puts our customers at a competitive advantage especially when it comes to identifying putative neoantigens, as well as identifying novel biomarker signatures. Neoantigens can arise from any gene in the genome, therefore, accuracy in calculating neoantigen load or comprehensively identifying neoantigens is contingent on having uniform coverage across the whole exome. The ACE Cancer Exome identifies candidate neoantigens that would have otherwise been missed by a standard exome. Positional analysis of the peptide mutations and binding potential across the SYN1 gene (Figure 3, Panel A), shows the number of predicted binding peptides that are captured in the augmented green region only (ACE supplementation) these peptides would have been completely missed by a conventional offering. The colors indicate the various Class I HLA alleles interrogated. Gene-wide sequencing of the SYN1 gene (Figure 3., Panel B) illustrates the coverage provided by a standard exome assay (blue region) and the gaps filled in by ACE augmentation (green region). Personalis provides both the blue (standard) and green (ACE) regions. A Figure 3: Neoantigens detected through ACE augmentation which would have otherwise been missed using standard exome assays, as demonstrated for the SYN1 gene. B Precision Genomics for Immuno-Oncology
6 Personalis, Inc. ACE Cancer Transcriptome Comprehensive characterization of tumor gene expression is an important overlay for interpreting somatic mutations, identifying neoantigens, assessing expression of immune checkpoint genes, and identifying prognostic expression signatures. The ACE Cancer Transcriptome, as part of ACE ImmunoID, sequences the tumor specimen at 100 million total reads. The same augmented, high accuracy coverage described for the ACE Cancer Exome is also available through our ACE Cancer Transcriptome enrichment protocol. Our enrichment protocol directly selects for transcripts using the optimized ACE capture probes, eliminating background and focusing the sequencing on regions of interest. When compared to a standard exome enrichment protocol, the ACE Cancer Transcriptome shows more uniform and deeper coverage across the entire gene (Figure 4). In addition, because we use the most current gene definitions, the ACE Cancer Transcriptome covers exons that are missing in standard annotation and other exon capture methods (Figure 5). A B Figure 4: Samples were prepared both with a standard exome capture method (panel A) and with the ACE Cancer Transcriptome Protocol (panel B). Five exomes of the BCR gene are shown. The ACE Cancer Transcriptome Protocol shows deeper and more even coverage across all give exome regions. A B Figure 5: Samples were prepared with both the standard exome capture method (panel A) and the ACE Cancer Trancriptome (panel B). Two exomes of the AFF3 gene are shown. The standard exome capture method misses the second exon while the ACE Cancer Transcriptome protocol shows deeper and more even coverage of both.
7 ACE ImmunoID Bioinformatics and reporting High quality genomic and transcriptomic data from ACE ImmunoID is run through our robust somatic pipeline to comprehensively profile the tumor including single nucleotide variants (SNVs), insertions and deletions (indels), fusions, and expression data. We provide both raw data files and reporting for DNA and RNA through our somatic pipelines. A summary of our standard deliverables is shown below: For DNA Analysis For RNA Analysis Raw data files: FASTQ, BAM Somatic variant (SNV, indel) analysis and report: VCF file Somatic variant annotation: VAR file Filtering and annotation of variants by cancer relevance and frequency Quality control report and statistical summary report Raw data files: FASTQ, BAM Variant (SNV, indel) analysis and report: VCF file Gene-associated variant analysis with additional filtering by cancer relevance Fusion gene analysis and report Gene-based expression results Quality control report and statistical summary report Precision Genomics for Immuno-Oncology
8 Personalis, Inc. Informing biomarker discovery and personalized therapy development NeoantigenID and ImmunogenomicsID, advanced analytical components of ACE ImmunoID, go a step beyond our standard bioinformatics reporting to provide summarized analytics on key areas of cancer biology in an easy-to-interpret format. NeoantigenID While tumor mutational burden (TMB) has been found to have some correlation with immunotherapy success 4, studies comparing the predictive utility of TMB and neoantigen load suggest that there is an even higher predicted clinical benefit in patients with higher neoantigen loads 5. Neoantigens are derived from tumor-specific somatic mutations and are therefore present only on the surface of cancer cells and not in healthy tissue. As a result, neoantigens can be used to train the immune system to distinguish healthy tissue from tumor tissue, making these tumor-specific peptides promising targets for personalized cancer vaccines and adoptive cell therapies. Powered by our Neoantigen Pipeline (Figure 6), NeoantigenID provides both TMB and neoantigen load, and also comprehensively identifies all potentially immunogenic neoantigens. Additionally, NeoantigenID includes metrics which may help guide candidate neoantigen selection such as HLA Class I and Class II typing, similarity-to-self, similarity-to-known-antigens, and an immunogenicity score 6. A list of top ten neoantigens, ranked based on MHC-binding prediction, is also provided.
9 ACE ImmunoID Neoantigen Analytics Engine Figure 6: Personalis Neoantigen Analytics Engine consists of several modules that inform neoantigen selection. Precision Genomics for Immuno-Oncology
10 Personalis, Inc. ImmunogenomicsID ImmunogenomicsID complements NeoantigenID to further elucidate the tumor and its microenvironment, providing genomic characterization of genes associated with key immunooncology areas such as antigen processing machinery (APM), immune modulation, adaptive and innate immune response, tumor-associated antigens (TAAs), amongst others. Metrics provided include tumor mutational burden (TMB) and reporting on gene-level expression (TPM), variant type (SNVs, indels, fusions), variant expression, DNA and RNA allelic fraction (>5%), HLA Class I somatic mutation variant calls, as well as population database searches. HLA HLA Class I somatic variants Antigen Presentation Machinery e.g. HLA, B2M, TAP, proteasome, ERAP1 Cytokines & Chemokines e.g. Interleukens, CXCL1,9,10,12, CXCR3 Analytics Immune Modulators e.g. OX40, LAG-3, TIM3, KIR, PD-L1, CTLA-4, ICOS Cytotoxicity e.g. GNLY, GZMA, GZMB, GAMH, PRF1 Immunogenomics and Neoantigen Discovery Adaptive & Innate Immune Response e.g. AIF1, IL2, IRF1, STA1, VCAM1 TAAs e.g. PRAME, MAGE, SSX-2, MUC1, CTAG1B (NY-ESO-1) Repair & Replication e.g. MMR, POL-E, MLH-1, BRCA1, BRCA2 Footnotes 4. Goodman, AM et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther Nov; 16(11): Laus, M. et al. Mutational and putative neoantigen load predict clinical benefit of adoptive t-cell therapy in melanoma. Nature Communications. 2017Nov; 8: Our immunogenicity score is based on internal algorithms derived from Callis et al. PLoS Comput Biol Oct:9(10):e
11 ACE ImmunoID An all-in-one immunogenomics solution By integrating high quality, comprehensive genomic and transcriptomic data, the ACE ImmunoID Platform not only supports a range of novel therapies including neoantigen-based cancer vaccines and adoptive cell therapies, it also supports biomarker discovery for checkpoint modulators. Further, this platform can be used to evaluate the efficacy of multi-modal treatments spanning immunotherapy, targeted therapy, and chemotherapy. Get In Touch To learn more about how our platform can transform your biomarker discovery and clinical development programs, contact us at info@personalis.com. Precision Genomics for Immuno-Oncology
12 Sales Contact United States Europe Other Countries Personalis, Inc O Brien Drive, Menlo Park, CA GENOME4 ( ) Personalis, Inc. All rights reserved. Personalis, ACE, ACE ImmunoID and ACE Cancer Transcriptome are registered trademarks of Personalis, Inc., ( Personalis ) in the United States and/or other countries A
ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics
ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics Precision Genomics for Immuno-Oncology Personalis, Inc. ACE ImmunoID When one biomarker doesn t tell the whole
More informationAVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
More informationNGS IN ONCOLOGY: FDA S PERSPECTIVE
NGS IN ONCOLOGY: FDA S PERSPECTIVE ASQ Biomed/Biotech SIG Event April 26, 2018 Gaithersburg, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration (FDA) Center for
More informationNGS ONCOPANELS: FDA S PERSPECTIVE
NGS ONCOPANELS: FDA S PERSPECTIVE CBA Workshop: Biomarker and Application in Drug Development August 11, 2018 Rockville, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration
More informationEnterprise Interest Thermo Fisher Scientific / Employee
Enterprise Interest Thermo Fisher Scientific / Employee A next-generation sequencing assay to estimate tumor mutation load from FFPE research samples Fiona Hyland. Director of R&D, Bioinformatics Clinical
More informationAVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB
Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation
More informationHARNESS THE POWER OF THE IMMUNE SYSTEM TO FIGHT CANCER
OncoPept TM HARNESS THE POWER OF THE IMMUNE SYSTEM TO FIGHT CANCER OncoPept identifies and delivers priortized T-cell neo-epitopes from the patient's tumor mutanome 2 What is OncoPept? OncoPept is an integrated
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationWhole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute
Whole Genome and Transcriptome Analysis of Anaplastic Meningioma Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Outline Anaplastic meningioma compared to other cancers Whole genomes
More informationPersonalis ACE Clinical Exome The First Test to Combine an Enhanced Clinical Exome with Genome- Scale Structural Variant Detection
Personalis ACE Clinical Exome The First Test to Combine an Enhanced Clinical Exome with Genome- Scale Structural Variant Detection Personalis, Inc. 1350 Willow Road, Suite 202, Menlo Park, California 94025
More informationAn innovative multi-dimensional NGS approach to understanding the tumor microenvironment and evolution
An innovative multi-dimensional NGS approach to understanding the tumor microenvironment and evolution James H. Godsey, Ph.D. Vice President, Research & Development Clinical Sequencing Division (CSD) Life
More informationTumor mutational burden and its transition towards the clinic
Tumor mutational burden and its transition towards the clinic G C C A T C A C Wolfram Jochum Institute of Pathology Kantonsspital St.Gallen CH-9007 St.Gallen wolfram.jochum@kssg.ch 30th European Congress
More informationPRECISION INSIGHTS. GPS Cancer. Molecular Insights You Can Rely On. Tumor-normal sequencing of DNA + RNA expression.
PRECISION INSIGHTS GPS Cancer Molecular Insights You Can Rely On Tumor-normal sequencing of DNA + RNA expression www.nanthealth.com Cancer Care is Evolving Oncologists use all the information available
More informationGolden Helix s End-to-End Solution for Clinical Labs
Golden Helix s End-to-End Solution for Clinical Labs Steven Hystad - Field Application Scientist Nathan Fortier Senior Software Engineer 20 most promising Biotech Technology Providers Top 10 Analytics
More informationAbstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction
Optimization strategy of Copy Number Variant calling using Multiplicom solutions Michael Vyverman, PhD; Laura Standaert, PhD and Wouter Bossuyt, PhD Abstract Copy number variations (CNVs) represent a significant
More informationWelcome. Nanostring Immuno-Oncology Summit. September 21st, FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
Welcome Nanostring Immuno-Oncology Summit September 21st, 2017 1 FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. Agenda 4:00-4:30
More informationDaniel Lieber, Ph.D. Senior Scientist, Computational Biology Foundation Medicine, Cambridge, MA. AACR 2017: Clinical Biomarkers April 3, 2017
Validation & clinical feasibility of a comprehensive genomic profiling assay to identify likely immunotherapy responders through tumor mutational burden (TMB) Daniel Lieber, Ph.D. Senior Scientist, Computational
More informationNGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation
NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation Michael R. Rossi, PhD, FACMG Assistant Professor Division of Cancer Biology, Department of Radiation Oncology Department
More informationPerformance Characteristics BRCA MASTR Plus Dx
Performance Characteristics BRCA MASTR Plus Dx with drmid Dx for Illumina NGS systems Manufacturer Multiplicom N.V. Galileïlaan 18 2845 Niel Belgium Table of Contents 1. Workflow... 4 2. Performance Characteristics
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu HSL GeneticEpi Center,
More informationSimple, rapid, and reliable RNA sequencing
Simple, rapid, and reliable RNA sequencing RNA sequencing applications RNA sequencing provides fundamental insights into how genomes are organized and regulated, giving us valuable information about the
More informationAD (Leave blank) TITLE: Genomic Characterization of Brain Metastasis in Non-Small Cell Lung Cancer Patients
AD (Leave blank) Award Number: W81XWH-12-1-0444 TITLE: Genomic Characterization of Brain Metastasis in Non-Small Cell Lung Cancer Patients PRINCIPAL INVESTIGATOR: Mark A. Watson, MD PhD CONTRACTING ORGANIZATION:
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu Director & Associate
More informationDISCOVER MORE WITH LESS SAMPLE. nanostring.com/3d
nanostring.com/3d DISCOVER MORE WITH LESS SAMPLE. WHY COMPROMISE? ncounter Vantage ASSAYS POWERED BY 3D BIOLOGY TECHNOLOGY Don t let sample volume limit your analytical aspirations. Quantify DNA, RNA,
More informationComprehensive genomic profiling for various solid tumors
Content Highlight Test Specification Test Content Performance Validation Test Report I II III IV V The NovoPM TM comprehensive cancer genomic profiling test Comprehensive genomic profiling for various
More informationCancer Gene Panels. Dr. Andreas Scherer. Dr. Andreas Scherer President and CEO Golden Helix, Inc. Twitter: andreasscherer
Cancer Gene Panels Dr. Andreas Scherer Dr. Andreas Scherer President and CEO Golden Helix, Inc. scherer@goldenhelix.com Twitter: andreasscherer About Golden Helix - Founded in 1998 - Main outside investor:
More informationAdvance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library
Advance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library Marilou Wijdicks International Product Manager Research For Life Science Research Only. Not for Use in Diagnostic Procedures.
More informationEvidence for antigen-driven TCRβ chain convergence in the tumor infiltrating T cell repertoire
Evidence for antigen-driven TCRβ chain convergence in the tumor infiltrating T cell repertoire Geoffrey M. Lowman, PhD Senior Staff Scientist EACR - 02 July 2018 For Research Use Only. Not for use in diagnostic
More informationAnalysis with SureCall 2.1
Analysis with SureCall 2.1 Danielle Fletcher Field Application Scientist July 2014 1 Stages of NGS Analysis Primary analysis, base calling Control Software FASTQ file reads + quality 2 Stages of NGS Analysis
More informationRegulatory Landscape for Precision Medicine
Regulatory Landscape for Precision Medicine Adam C. Berger, Ph.D. Office of In Vitro Diagnostics and Radiological Health, FDA FOCR-Alexandria A Blueprint for Breakthrough Meeting September 13, 2017 1 What
More informationCancer immunity and immunotherapy. General principles
1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or
More informationDetection of immune cell checkpoint and functional markers in the tumor microenvironment by the RNA in situ hybridization RNAscope assay
pplication Note Immunotherapy Detection of immune cell checkpoint and functional markers in the tumor microenvironment by the RN in situ hybridization RNscope assay Ming-Xiao He, Na Li, Courtney nderson,
More informationForeign antigens in human cancers
Foreign antigens in human cancers Lorenzo Fanchi PhD student, Ton Schumacher Lab ESMO Preceptorship on Immuno-Oncology May 26th, 2017 IMMUNE CHECKPOINT INHIBITION SHOWS CLINICAL BENEFIT IN DIFFERENT TUMOR
More informationAbSeq on the BD Rhapsody system: Exploration of single-cell gene regulation by simultaneous digital mrna and protein quantification
BD AbSeq on the BD Rhapsody system: Exploration of single-cell gene regulation by simultaneous digital mrna and protein quantification Overview of BD AbSeq antibody-oligonucleotide conjugates. High-throughput
More informationDIRECT IDENTIFICATION OF NEO-EPITOPES IN TUMOR TISSUE
DIRECT IDENTIFICATION OF NEO-EPITOPES IN TUMOR TISSUE Eustache Paramithiotis PhD Vice President, Biomarker Discovery & Diagnostics 17 March 2016 PEPTIDE PRESENTATION BY MHC MHC I Antigen presentation by
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationImportance of Methodology Certification and Accreditations to Perform Assays. Stan Hamilton, MD Head, Pathology and Laboratory Medicine
Importance of Methodology Certification and Accreditations to Perform Assays Stan Hamilton, MD Head, Pathology and Laboratory Medicine 1 Disclosures No disclosures relevant to this presentation 2 A bad
More informationCurrent practice, needs and future directions in immuno-oncology research testing
Current practice, needs and future directions in immuno-oncology research testing Jose Carlos Machado IPATIMUP - Porto, Portugal ESMO 2017- THERMO FISHER SCIENTIFIC SYMPOSIUM Immune Therapies are Revolutionizing
More informationInternational Society of Breast Pathology. Immune Targeting in Breast Cancer. USCAP 2017 Annual Meeting
International Society of Breast Pathology USCAP 2017 Annual Meeting Immune Targeting in Breast Cancer Ashley Cimino-Mathews, MD Assistant Professor of Pathology and Oncology The Johns Hopkins Hospital
More informationSupplementary Tables. Supplementary Figures
Supplementary Files for Zehir, Benayed et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients Supplementary Tables Supplementary Table 1: Sample
More informationFrequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
More informationTITLE: High throughput sequencing of germline and tumor from men with early-onset, metastatic prostate cancer
AWARD NUMBER: W81XWH-13-1-0371 TITLE: High throughput sequencing of germline and tumor from men with early-onset, metastatic prostate cancer PRINCIPAL INVESTIGATOR: A. Cooney, M.D. CONTRACTING ORGANIZATION:
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationScreening for novel oncology biomarker panels using both DNA and protein microarrays. John Anson, PhD VP Biomarker Discovery
Screening for novel oncology biomarker panels using both DNA and protein microarrays John Anson, PhD VP Biomarker Discovery Outline of presentation Introduction to OGT and our approach to biomarker studies
More informationEXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)
Dr Kate Goodhealth Goodhealth Medical Clinic 123 Address Road SUBURBTOWN NSW 2000 Melanie Citizen Referring Doctor Your ref Address Dr John Medico 123 Main Street, SUBURBTOWN NSW 2000 Phone 02 9999 9999
More informationSupplementary Figure 1. Estimation of tumour content
Supplementary Figure 1. Estimation of tumour content a, Approach used to estimate the tumour content in S13T1/T2, S6T1/T2, S3T1/T2 and S12T1/T2. Tissue and tumour areas were evaluated by two independent
More informationSingle-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA
www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2016 Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) DNA Supplementary Materials
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationAssessing Laboratory Performance for Next Generation Sequencing Based Detection of Germline Variants through Proficiency Testing
Assessing Laboratory Performance for Next Generation Sequencing Based Detection of Germline Variants through Proficiency Testing Karl V. Voelkerding, MD Professor of Pathology University of Utah Medical
More informationThe use of diagnostic FFPE material in cancer epidemiology research
The use of diagnostic FFPE material in cancer epidemiology research Neil O Callaghan Genetic Epidemiology Laboratory Department of Pathology The University of Melbourne www.pedigree.org.au Overview Who
More informationComprehensive Tumor Profiling of Immune Response and Systems Biology. HTG EdgeSeq Immuno-Oncology Assay. HTG EdgeSeq Oncology Biomarker Panel
Comprehensive Tumor Profiling of Immune Response and Systems Biology HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Oncology Biomarker Panel A new frontier in the research of cancer therapeutics HTG provides
More informationA Multifaceted Immunomonitoring to Identify Predictive Biomarkers for the Clinical Outcome of Immunotherapy-Treated Melanoma Patients
A Multifaceted Immunomonitoring to Identify Predictive Biomarkers for the Clinical Outcome of Immunotherapy-Treated Melanoma Patients Immunotherapy Biomarkers: Overcoming the Barriers NIH, Bethesda, April
More informationDNA-seq Bioinformatics Analysis: Copy Number Variation
DNA-seq Bioinformatics Analysis: Copy Number Variation Elodie Girard elodie.girard@curie.fr U900 institut Curie, INSERM, Mines ParisTech, PSL Research University Paris, France NGS Applications 5C HiC DNA-seq
More informationEnterprise Interest Nothing to declare
Enterprise Interest Nothing to declare Immunotherapy Biomarker Identification with NGS Technology Andrew Felton VP Marketing and Product Management, Ion Torrent Business Monday, September 4, 2017 The world
More informationBreast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS
Breast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS dr sc. Ana Krivokuća Laboratory for molecular genetics Institute for Oncology and
More informationDavid Tamborero, PhD
David Tamborero, PhD Lopez-Bigas' lab Study of Tumor Genomes Study of Tumor Genomes Study sequencing data of tumors to understand the biological mechanisms shaping the mutational processes observed at
More informationAPPLICATION NOTE. Highly reproducible and Comprehensive Proteome Profiling of Formalin-Fixed Paraffin-Embedded (FFPE) Tissues Slices
APPLICATION NOTE Highly reproducible and Comprehensive Proteome Profiling of Formalin-Fixed Paraffin-Embedded (FFPE) Tissues Slices INTRODUCTION Preservation of tissue biopsies is a critical step to This
More informationComprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast. PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information
More informationDigitizing the Proteomes From Big Tissue Biobanks
Digitizing the Proteomes From Big Tissue Biobanks Analyzing 24 Proteomes Per Day by Microflow SWATH Acquisition and Spectronaut Pulsar Analysis Jan Muntel 1, Nick Morrice 2, Roland M. Bruderer 1, Lukas
More informationNeoantigen Identification using ATLAS Across Multiple Tumor Types Highlights Limitations of Prediction Algorithms
Neoantigen Identification using ATLAS Across Multiple Tumor Types Highlights Limitations of Prediction Algorithms Wendy Broom, Ph.D. Keystone: Translational Systems Immunology, Snowbird February 1st 2018
More informationSummary... 2 TRANSLATIONAL RESEARCH Tumour gene expression used to direct clinical decision-making for patients with advanced cancers...
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 TRANSLATIONAL RESEARCH... 3 Tumour gene expression used to direct clinical decision-making for patients with advanced
More informationA fresh approach to Immuno-oncology: Ex vivo analysis of drug efficacy in fresh patient tumortissue
A fresh approach to Immuno-oncology: Ex vivo analysis of drug efficacy in fresh patient tumortissue Soner Altiok, MD, PhD Chief Scientific Officer Nilogen Oncosystems Tampa, Florida - Nilogen Oncosystems,
More informationAnalysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers
Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers Gordon Blackshields Senior Bioinformatician Source BioScience 1 To Cancer Genetics Studies
More informationDr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory
Dr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory Personalised Therapy/Precision Medicine Selection of a therapeutic drug based on the presence or absence of a specific
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationOncology Biomarker Panel
Oncology Biomarker Panel HTG EdgeSeq Oncology Biomarker Panel The HTG EdgeSeq Oncology Biomarker Panel profiles tumor samples in order to identify therapeutic targets and drug response markers using an
More informationMEDICAL GENOMICS LABORATORY. Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG)
Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG) Ordering Information Acceptable specimen types: Blood (3-6ml EDTA; no time limitations associated with receipt) Saliva (OGR-575 DNA Genotek;
More informationClinical Utility of Actionable Genome Information in Precision Oncology Clinic
Indian Ocean Rim 2017 Laboratory Haematology Congress 2017. 6.18-19, Singapore Clinical Utility of Actionable Genome Information in Precision Oncology Clinic Reimbursement program for NGS panel tests in
More informationInvestigating rare diseases with Agilent NGS solutions
Investigating rare diseases with Agilent NGS solutions Chitra Kotwaliwale, Ph.D. 1 Rare diseases affect 350 million people worldwide 7,000 rare diseases 80% are genetic 60 million affected in the US, Europe
More informationHOW TO MAXIMIZE PATIENT RECRUITMENT IN ONCOLOGY TRIALS A BIOPHARMA DIVE PLAYBOOK
HOW TO MAXIMIZE PATIENT RECRUITMENT IN ONCOLOGY TRIALS A BIOPHARMA DIVE PLAYBOOK Over the last several decades, patient recruitment for clinical trials has remained a major barrier to rapid execution of
More informationGenomics in the Clinical Practice - Today and Tomorrow
Genomics in the Clinical Practice - Today and Tomorrow Pier Giuseppe Pelicci, MD-PhD Director of Research, IEO, Milan Professor of Pathology, University of Milan Workshop on Processing of Genomic Information:
More informationIntroduction of an NGS gene panel into the Haemato-Oncology MPN service
Introduction of an NGS gene panel into the Haemato-Oncology MPN service Dr. Anna Skowronska, Dr Jane Bryon, Dr Samuel Clokie, Dr Yvonne Wallis and Professor Mike Griffiths West Midlands Regional Genetics
More informationunderlying metastasis and recurrence in HNSCC, we analyzed two groups of patients. The
Supplementary Figures Figure S1. Patient cohorts and study design. To define and interrogate the genetic alterations underlying metastasis and recurrence in HNSCC, we analyzed two groups of patients. The
More informationNew Developments in the Treatment of Colorectal Cancer. Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre
New Developments in the Treatment of Colorectal Cancer Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre Personalized Medicine Currently already part of oncology:
More informationTITLE: Total RNA Sequencing Analysis of DCIS Progressing to Invasive Breast Cancer.
AWARD NUMBER: W81XWH-14-1-0080 TITLE: Total RNA Sequencing Analysis of DCIS Progressing to Invasive Breast Cancer. PRINCIPAL INVESTIGATOR: Christopher B. Umbricht, MD, PhD CONTRACTING ORGANIZATION: Johns
More informationThe feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients
The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients ASSC Scientific Meeting 13 th October 2016 Prof Andrew Barbour UQ SOM
More informationRoadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers. Richard Simon, J Clin Oncol 23:
Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers. Richard Simon, J Clin Oncol 23:7332-7341 Presented by Deming Mi 7/25/2006 Major reasons for few prognostic factors to
More informationDecipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy
Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Cystectomy Contact the GenomeDx Customer Support Team 1.888.792.1601 (toll-free) customersupport@genomedx.com
More informationSeptember 23, The Role of In Vitro Diagnostic Tests in Pediatric Master Protocol Development
The Role of In Vitro Diagnostic Tests in Pediatric Master Protocol Development September 23, 2016 Anand Pathak, MD, PhD, MPH Medical Officer Molecular Genetics Branch Division of Molecular Genetics and
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationIntegration of Cancer Genome into GECCO- Genetics and Epidemiology of Colorectal Cancer Consortium
Integration of Cancer Genome into GECCO- Genetics and Epidemiology of Colorectal Cancer Consortium Ulrike Peters Fred Hutchinson Cancer Research Center University of Washington U01-CA137088-05, PI: Peters
More informationMEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)
Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Ordering Information Acceptable specimen types: Fresh blood sample (3-6 ml EDTA; no time limitations associated with receipt)
More informationmirna Whole Transcriptome Assay
mirna Whole Transcriptome Assay HTG EdgeSeq mirna Whole Transciptome Assay The HTG EdgeSeq mirna Whole Transcriptome Assay (WTA) is a next generation sequencing (NGS) application that measures the expression
More informationMutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research
Mutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research Application Note Authors John McGuigan, Megan Manion,
More informationPersonalized Cancer Neoantigen Vaccines
Personalized Cancer Neoantigen Vaccines Turning the Immune System Against Your own Unique Tumour-Specific Antigens 3 rd Annual Advances in Immuno-Oncology Congress London, May 24, 2018 Agnete Fredriksen,
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2011 June 30, 2012 Formula Grant Overview The National Surgical
More informationAccel-Amplicon Panels
Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation
More informationMulti-omics data integration colon cancer using proteogenomics approach
Dept. of Medical Oncology Multi-omics data integration colon cancer using proteogenomics approach DTL Focus meeting, 29 August 2016 Thang Pham OncoProteomics Laboratory, Dept. of Medical Oncology VU University
More informationMatthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory
Molecular Profiling Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory Objectives Defining molecular profiling Technologies Why do we profile tumors? Current testing &
More informationNGS Gateway Lab Services
TM NGS Gateway Lab Services Accelerating Precision Medicine Design a Complete Genomic Testing Portfolio with Turnkey Assays About NGS Gateway Lab Services TM Designed to provide a gateway to your own in-house
More informationNext generation diagnostics Bringing high-throughput sequencing into clinical application
Next generation diagnostics Bringing high-throughput sequencing into clinical application Leonardo A. Meza-Zepeda, PhD Translational Genomics Group Institute for Cancer Research Leonardo.Meza-Zepeda@rr-research.no
More informationGPS Cancer. The Era of Complete Genomics and Proteomics is Here. Advanced molecular profiling to inform personalized treatment strategies
MOLECULAR PROFILING GPS Cancer The Era of Complete Genomics and Proteomics is Here Advanced molecular profiling to inform personalized treatment strategies www.nanthealth.com What information do you need
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationSynergistic combinations of targeted immunotherapy to combat cancer
Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic
More informationInterpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment. Lorcan Sherry, CSO OracleBio
Interpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment Lorcan Sherry, CSO OracleBio Company Overview OracleBio is a specialised CRO providing
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2011 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2011 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The NSABP Foundation
More informationMolecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy
Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,
More informationHighlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationPersonalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
More information